Several studies have also observed an initial downtrend in eGFR with commonly used CKD treatments like RASi [31], sodium-glucose cotransporter 2 inhibitors (SGLT-2i) [32], and non-steroidal MRAs [33]. Here, SLC5A2 is linked to chronic kidney disease.